RCS - NanoViricides, Inc. - NanoViricides: Clinical Trials, Antiviral NV-CoV-2
29/06/2023 13:00
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230629:nRSc2981Ea&default-theme=true
RNS Number : 2981E NanoViricides, Inc. 29 June 2023
NanoViricides Announces that Clinical Trials of Its Broad-Spectrum Antiviral
Drug NV-CoV-2 Have Begun
SHELTON, CT / ACCESSWIRE / June 29, 2023 / NanoViricides, Inc. (NYSE
American:NNVC) (https://pr.report/-27ihNfm) (the "Company") reports that
clinical trials of its broad-spectrum antiviral drug NV-CoV-2 began on June
17, 2023 with two oral drug products: (i) NV-CoV-2 Oral Syrup, and (ii)
NV-CoV-2 Oral Gummies.
"We believe that the start of the Phase 1a/1b safety and efficacy clinical
trial is an important milestone not only for NanoViricides and Karveer
Meditech, India, but for the whole world," said Dr. Anil Diwan, Ph.D.,
President and Executive Chairman of the Company, explaining, "NV-CoV-2 is
aimed at satisfying the as-yet-unmet medical need for a highly effective
broad-spectrum, pan-coronavirus drug that can be used for all patient
populations. Further, we believe the nanoviricides technology adds a valuable
tool to the basket of worldwide preparedness and response strategies for
future viral pandemics."
The Company is a clinical-stage global leader in the development of highly
effective antiviral therapies based on a novel nanomedicines platform, called
"nanoviricides". NV-CoV-2, the Company's lead drug candidate for the treatment
of coronavirus infections including COVID and potentially many cases of long
COVID, has now entered Phase 1a/1b human clinical trials that are sponsored by
Karveer Meditech Pvt. Ltd. India, the Company's Licensee and co-developer in
India (see below).
The Clinical Trial Will Evaluate Both Safety and Initial Efficacy Indications
in COVID patients:
Phase 1a will assess the safety and tolerability of a new molecule (drug
product NV-CoV-2 containing API NV-387) in healthy subjects. In Phase 1b,
patients with mild to moderate COVID-19 will be enrolled to assess indication
of efficacy.
The Single Dosing of Healthy Volunteers portion of the Phase 1a began with the
dosing of a first set of volunteers on June 17, 2023. This set of volunteers
was successfully discharged after a 48 hours in-hospital stay for observation,
and will be further assessed in a final out-person visit as per the protocol.
Further recruitments and dosings are scheduled as per the protocol.
NV-387 Is a First-in-Class Chemical Nanomachine that Acts by a Novel Mechanism
of Action:
The Company calls the antiviral mechanism of NV-387 "Re-Infection Blocker."
The drug is designed to directly attack the virus particle with a
multi-pronged attack and thereby disable the virus completely so that it
cannot further infect human cells and the infection cannot progress. The
Company believes that this novel antiviral mechanism can become an important
new tool for worldwide pandemic preparedness and response strategies to combat
future viral pandemics.
NV-387 has demonstrated strong pan-coronavirus effectiveness as well as
excellent safety in pre-clinical studies. Both our oral drug products: (i)
NV-CoV-2 Oral Syrup, and (ii) NV-CoV-2 Oral Gummies are formulations of the
same active pharmaceutical ingredient (API), NV-387.
The Team Behind the Clinical Trials:
The Company previously announced that it has executed a License Agreement with
Karveer Meditech Pvt. Ltd., Kolhapur, India ("Karveer"). Under this Agreement,
Karveer has the right to commercialize the Company's COVID drugs, NV-CoV-2 and
NV-CoV-2-R, in India. To enable commercialization, Karveer has undertaken
Clinical Development and Evaluation and is sponsoring these two drugs in India
for this purpose.
Karveer Meditech has retained the Clinical Trials Organization, PristynCR
Solutions, Pvt. Ltd., Aurangabad, Maharashtra, India, to develop and prosecute
the clinical trials applications and conduct the clinical trials.
The Phase 1a/1b clinical trial labeled KM-NVCoV2-001 is being conducted at a
single site, Clinical Research Unit in the Department of Clinical
Pharmacology, Mahatma Gandhi Mission's Medical College and Hospital,
Aurangabad, India.
The clinical trial protocol and information can be found in India's official
clinical trials registry, https://ctri.nic.in/Clinicaltrials/pubview.php
(https://pr.report/Ug0yx6Ou) by entering the sponsor's name "Karveer Meditech"
and selecting the search criterion "Sponsor."
About Mahatma Gandhi Mission's Medical College and Hospital, Aurangabad, India
Mahatma Gandhi Mission's Medical College and Hospital is a private, "NABH
accredited" medical college hospital (A++ grade). The hospital has 700 beds,
including 85 beds of Intensive care units. The hospital provides health care
services through various charity schemes that enable free healthcare services
to the eligible public. Additionally, the hospital also provides fee-paid
specialty services and medical care. The hospital provides medical and
surgical services along with super-speciality services such as Cardiology,
Nephrology, Plastic Surgery, Neurosurgery, and Urology.
The hospital is well-supported with state of the art diagnostic laboratories
which includes a NABL accredited Central Pathology Laboratory, Radiology and
other services.
The hospital treats over 4,000 patients including out-patients and in-patients
daily. The hospital has treated well over 20,000 mild, another 20,000+
moderate, and at least 12,000+ severe cases of COVID-19.
The Clinical Trial Unit at the Hospital has conducted multiple clinical trials
for COVID drugs in different clinical phases.
About PristynCR Solutions Pvt. Ltd.
PristynCR Solutions Pvt. Ltd. is a contract research organization helping
global enterprises to advance their regulatory and clinical research. Apart
from Pharmaceutical trials services PristynCR also provides Medical Writing,
Data Management, Pharmacovigilance and Regulatory Insight services; in short,
a full-service stack from drug discovery to approval including tech transfer
requirements.
About Karveer Meditech Private Limited
Karveer Meditech Private Limited is a small and aspiring dynamic
pharmaceutical company in India. It has developed and commercialized in local
markets more than a dozen different generic and semi-branded pharmaceutical
drugs as well as Ayurvedic medicines and vitaminized nutritional supplement
protein powder products. It was co-founded by Dr. Anil Diwan, who serves as a
Director and is a passive investor. Dr. Diwan is also co-founder of and
President and Chairman of the Board of NanoViricides. Karveer Meditech is
independently managed by its Managing Director in India.
About NanoViricides (https://pr.report/gAKyQrJV)
NanoViricides, Inc. (the "Company") (www.nanoviricides.com
(https://pr.report/WDSdH3kz) ) is a clinical stage company that is creating
special purpose nanomaterials for antiviral therapy. The Company's novel
nanoviricide® class of drug candidates are designed to specifically attack
enveloped virus particles and to dismantle them. Our lead drug candidate is
NV-CoV-2 for the treatment of COVID caused by SARS-CoV-2 coronavirus. Our
other advanced candidate is NV-HHV-1 for the treatment of Shingles. The
Company cannot project exact dates for the regulatory activities in
progressing its drug candidates because of the Company's significant
dependence on external collaborators and consultants. The Company is currently
focused on advancing NV-CoV-2 through Phase I/II human clinical trials.
NV-CoV-2 is the Company's nanoviricide drug candidate for COVID. NV-CoV-2-R is
another drug candidate for COVID that is made up of NV-CoV-2 with Remdesivir,
an already approved drug, encapsulated within its polymeric micelles.
Remdesivir is developed by Gilead. The Company has developed both of its own
drug candidates NV-CoV-2 and NV-CoV-2-R independently.
The Company is also developing a broad pipeline of drugs against a number of
viruses, with preclinical safety and effectiveness successes achieved already
in many cases. NanoViricides' platform technology and programs are based on
the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses
from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to
this technology for several drugs with specific targeting mechanisms for the
treatment of the following human viral diseases: Human Immunodeficiency Virus
(HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes
Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and
Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile
Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends
to obtain a license for poxviruses, enteroviruses, and other viruses that it
engages into research for, if the initial research is successful. TheraCour
has not denied any licenses requested by the Company to date. The Company's
business model is based on licensing technology from TheraCour Pharma Inc. for
specific application verticals of specific viruses, as established at its
foundation in 2005.
Disclosure Statement
This press release contains forward-looking statements that reflect the
Company's current expectation regarding future events. Actual events could
differ materially and substantially from those projected herein and depend on
a number of factors. Certain statements in this release, and other written or
oral statements made by NanoViricides, Inc. are "forward-looking statements"
within the meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934. You should not place undue
reliance on forward-looking statements since they involve known and unknown
risks, uncertainties and other factors that are, in some cases, beyond the
Company's control and that could, and likely will, materially affect actual
results, levels of activity, performance or achievements. The Company assumes
no obligation to publicly update or revise these forward-looking statements
for any reason, or to update the reasons actual results could differ
materially from those anticipated in these forward-looking statements, even if
new information becomes available in the future. Important factors that could
cause actual results to differ materially from the company's expectations
include, but are not limited to, those factors that are disclosed under the
heading "Risk Factors" and elsewhere in documents filed by the company from
time to time with the United States Securities and Exchange Commission and
other regulatory authorities. Although it is not possible to predict or
identify all such factors, they may include the following: demonstration and
proof of principle in preclinical trials that a nanoviricide is safe and
effective; successful development of our product candidates; our ability to
seek and obtain regulatory approvals, including with respect to the
indications we are seeking; the successful commercialization of our product
candidates; and market acceptance of our products. In particular, as is
customary, the Company must state the risk factor that the path to typical
drug development of any pharmaceutical product is extremely lengthy and
requires substantial capital. As with any drug development efforts by any
company, there can be no assurance at this time that any of the Company's
pharmaceutical candidates would show sufficient effectiveness and safety in
human clinical trials to lead to a successful pharmaceutical product,
including our coronavirus drug development program.
Contact:
NanoViricides, Inc.
info@nanoviricides.com
Public Relations Contact:
MJ Clyburn
TraDigital IR
clyburn@tradigitalir.com
SOURCE: NanoViricides, Inc.
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END NRAEAXKPADLDEFA